Roger Kuan focuses his practice on intellectual property procurement/portfolio management, IP transactions and strategic IP counseling for clients in the personalized/precision medicine (e.g., genomic sequencing platforms, computational genomics/bioinformatics, molecular diagnostics, etc.), digital health, life sciences tooling (e.g., biomanufacturing, analytical instrumentation, flow cytometry, etc.), medical device and chemical industries. He has extensive experience in intellectual property strategy and management, preparation and prosecution (utility/design patents, trademarks and trade dress), counseling and litigation, licensing and technology transactions, freedom-to-operate clearances, monetization, IP due diligence, IP risk recognition and mitigation, and dispute resolution.
He served as Director IP Counsel at a multinational biotechnology company, where he managed a team of lawyers and agents to support the worldwide IP needs of the company’s life sciences tooling, bio production/bio manufacturing, molecular diagnostics, and nucleic acid sequencing product platforms. Roger worked in the life sciences industry for several Fortune 500 pharmaceutical, medical device, and chemical companies. He held professional positions in the R&D, sales, engineering, and regulatory affairs organizations.
Santa Clara University School of Law, JD, 2004
California Polytechnic State University, MS, Environmental Engineering (biochemical engineering emphasis), with honors, 1999
University of California – Davis, BS, Toxicology, 1995
Do not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott from representing any other person or firm in any matter; and will not obligate McDermott to keep confidential the information you provide. McDermott cannot enter into an attorney-client relationship with you until McDermott has determined that doing so will not create a conflict of interest and until you and McDermott have entered into a written agreement or engagement letter that sets forth the terms of our relationship.